Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
來自世界衛生組織數據的 Semaglutide、Liraglutide 與自殺傾向的不成比例分析。
JAMA Netw Open 2024-08-20
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
葡萄糖樣肽-1 受體激動劑(GLP-1 RAs)與自殺行為之關聯:對食品藥物管理局不良事件報告系統(FAERS)的報告。
Expert Opin Drug Saf 2024-02-14
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
與semaglutide、liraglutide和tirzepatide相關的精神科不良事件:提交至EudraVigilance數據庫的個別案例安全報告的藥物警戒分析。
Int J Clin Pharm 2024-03-26
Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
GLP-1 受體激動劑與自殺或自我傷害行為之潛在關聯性探討:基於 FDA 不良事件報告系統資料庫的藥物監察研究。
BMC Med 2024-02-17
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
GLP-1 受體激動劑與自殺意念:歐洲藥物監視數據分析。
Pharmaceuticals (Basel) 2024-02-27
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
探討自殺念頭、自我傷害與 GLP-1 受體激動劑在減重治療中的關聯:來自藥物監察措施和揭示分析的見解。
Eur Neuropsychopharmacol 2024-05-02
Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
糖尿病和肥胖患者中,胰高血糖素樣肽-1受體激動劑與自殺意念和自我傷害的關聯:一項傾向加權的基於人群的隊列研究。
Diabetologia 2024-08-05
Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.
胰高血糖素樣肽-1 受體激動劑與自殺風險之間的關聯:全球藥物監測數據庫的綜合分析。
Diabetes Obes Metab 2024-08-20